Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Phase II Prospective Trial of Fixed Duration Obinutuzumab, Ibrutinib and, Venetoclax in an Elderly Cohort of Patients with Richter's Syndrome-Givers Regimen

Tamar Tadmor, Ohad Benjamini, Neta Goldschmidt, Natalia Kreiniz, Osnat Bairey, Reut Harel, Nadav Sarid, Tsofia Levi, Ofir Wolach, Yair Herishanu

Blood (2024) 144 (Supplement 1): 1862.

https://doi.org/10.1182/blood-2024-205236

Published: 2024

Journal Articles

Derivation and External Validation of a Venous Thromboembolism Risk Prediction Model in Patients with Acute Lymphoblastic Leukemia Receiving Asparaginase Therapy

Blood (2024) 144 (Supplement 1): 1250.

https://doi.org/10.1182/blood-2024-201997

Published: 2024

Journal Articles

Warburg-Effect Driven Lactic Acidosis Is Associated with Early Death in Patients with Lymphoma

Bahaa Atamna, Alon Rozental, Mohamed Haj Yahia, Ronit Gurion, Moshe Yeshurun, Pia Raanani, Ofir Wolach

Blood (2024) 144 (Supplement 1): 4476.

https://doi.org/10.1182/blood-2024-208234

Published: 2024

Journal Articles

Interferon Inhibits Netosis in Neutrophils Derived from Patients with Myeloproliferative Neoplasms in a Neutrophil Subpopulation-Specific Manner

Idan Goldberg, Shirly Partouche, Erez Halperin, Bahaa Atamna, Adi Shacham Abulafia, Saar Shapira, Aladin Samara, Ayala Gover-Proaktor, Avi Leader, Galia Spectre, Pia Raanani, Galit Granot, Ofir Wolach

Blood (2024) 144 (Supplement 1): 1762.

https://doi.org/10.1182/blood-2024-209795

Published: 2024

Journal Articles

Genotype-phenotype correlations in chronic granulomatous disease: insights from a large national cohort

Blood (2024) 144 (12): 1300–1313.

https://doi.org/10.1182/blood.2023022590

Published: 2024

Includes: Supplemental data

Journal Articles

Unraveling the Mechanism of Action of Bispecific T-Cell Engagers in B-Cell Acute Lymphoblastic Leukemia Using Advanced Single-Cell Multiomics

Anna Gurevich Shapiro, Eitan Winter, Yakir Moshe, Yonatan Katzenelenbogen, Diego Jaitin, Mor Zada, Oren Barboy, Ido Yofe, Paulina Chalan, San Truong Phan, Amir Giladi, Michael Shapiro, Renana Robinson, Eitan Kugler, Ofir Wolach, Irit Avivi Mazza, Ido Amit

Blood (2023) 142 (Supplement 1): 599.

https://doi.org/10.1182/blood-2023-188930

Published: 2023

Journal Articles

Daunorubicin/Cytarabine Liposome +/- Gemtuzumab Ozogamicin for Adult Patients with Newly Diagnosed, Low-Intermediate Risk, FLT3-Wild Type, AML: A Pilot Study

Chezi Ganzel, Avraham Frisch, Ofir Wolach, Yakir Moshe, Ellen Broide, Emmanuel Benayoun, Jacob M. Rowe, Yishai Ofran

Blood (2023) 142 (Supplement 1): 2892.

https://doi.org/10.1182/blood-2023-185052

Published: 2023

Journal Articles

Impact of Premedication Prior to Platelet Transfusion on Platelet Increment Among Hemato-Oncological Patients

Tamar Berger, Vered Yahalom, Odil Giladi, Eithan Kugler, Tzippy Shochat, Victoria Meirman, Ella Gal, Tetyana Klebovsky, Ofir Wolach, Moshe Yeshurun, Pia Raanani, Liat Shargian, Oren Pasvolsky

Blood (2023) 142 (Supplement 1): 5563.

https://doi.org/10.1182/blood-2023-181310

Published: 2023

Journal Articles

A Prospective, Phase-II Study to Evaluate the Efficacy and Safety of Obinutuzumab, Ibrutinib, and Venetoclax (GIVeRS) in Patients with Richter's Syndrome

Tamar Tadmor, Ohad Benjamini, Neta Goldschmidt, Natalia Kreiniz, Osnat Bairey, Reut Harel, Tsofia Inbar, Ofir Wolach, Yair Herishanu

Blood (2023) 142 (Supplement 1): 4640.

https://doi.org/10.1182/blood-2023-185569

Published: 2023

Journal Articles

Comparative Analysis of Clinical Outcomes and Healthcare Resource Utilization (HRU) in Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Unfit for High-Intensity Chemotherapy Treated with Venetoclax (VEN) Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative

Blood (2023) 142 (Supplement 1): 5173.

https://doi.org/10.1182/blood-2023-173283

Published: 2023

Journal Articles

Utility of Echocardiogram in Neutropenic Patients with Gram Positive Bacteremia: A Retrospective Study

Neta Sternbach, Pia Raanani, Dafna Yahav, Liat Shragian, Moshe Yeshurun, Ofir Wolach, Haim Ben zvi

Blood (2023) 142 (Supplement 1): 5830.

https://doi.org/10.1182/blood-2023-178346

Published: 2023

Journal Articles

Efficacy of Luspatercept in Low-Risk Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis

Irina Amitai, Ronit Gurion, Pia Raanani, Moshe Yeshurun, Ofir Wolach, Drorit Merkel, Yoav Amitai, Anat Gafter-Gvili, Liat Shargian

Blood (2023) 142 (Supplement 1): 6487.

https://doi.org/10.1182/blood-2023-189891

Published: 2023

Journal Articles

Warburg-Effect Driven Lactic Acidosis Is Associated with Early Death in Patients with Lymphoma

Bahaa Atamna, Pia Raanani, Ronit Gurion, Ofir Wolach

Blood (2023) 142 (Supplement 1): 6307.

https://doi.org/10.1182/blood-2023-187265

Published: 2023

Journal Articles

Gilteritinib and Venetoclax for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia - a Real-World Multicenter Retrospective Study

Eitan Kugler, Inbar Cohen, Ron Ram, Jonathan Canaani, Irina Amitai, Liat Shargian, Boaz Nachmias, Baher Krayem, Avraham Frisch, Itay Levi, Luiza Akria, Pia Raanani, Ofir Wolach, Eitan Kugler

Blood (2023) 142 (Supplement 1): 5911.

https://doi.org/10.1182/blood-2023-185488

Published: 2023

Journal Articles

Thrombin Generation Is Differentially Affected By Anticoagulants in Patients with Acute Lymphoblastic Leukemia - an Ex-Vivo Study

Avi Leader, Sarah Elitzur, Baruch Gavrieli, Henri M.H. Spronk, Magdolna Nagy, Rene Van Oerle, Galia Spectre, Shai Shimony, Yakir Moshe, Roaya Mahajna, Gil Gilad, Galia Avrahami, Shai Izraeli, Pia Raanani, Shlomit Barzilai-Birenboim, Ofir Wolach

Blood (2022) 140 (Supplement 1): 1252–1254.

https://doi.org/10.1182/blood-2022-163313

Published: 2022

Journal Articles

Clinical Predictors for Relapse Among Patients with AML Who Responded to Venetoclax-Based Treatment - a Real-World Prospective Analysis from the Revive Study Group

Blood (2022) 140 (Supplement 1): 9002–9004.

https://doi.org/10.1182/blood-2022-162140

Published: 2022

Journal Articles

Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By TP53 and IDH1/2 Mutation: Results from the AML Real World Evidence (ARC) Initiative

Blood (2022) 140 (Supplement 1): 11026–11028.

https://doi.org/10.1182/blood-2022-159615

Published: 2022

Journal Articles

Long-Term Follow-up of the Phase 3 Viale-a Clinical Trial of Venetoclax Plus Azacitidine for Patients with Untreated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Keith W. Pratz, Brian A. Jonas, Vinod A. Pullarkat, Michael J. Thirman, Jacqueline S. Garcia, Walter Fiedler, Kazuhito Yamamoto, Jianxiang Wang, Sung-Soo Yoon, Ofir Wolach, Jun-Ho Jang, Su-Peng Yeh, Grace Ku, Ying Zhou, Brenda Chyla, Jalaja Potluri, Courtney D. DiNardo

Blood (2022) 140 (Supplement 1): 529–531.

https://doi.org/10.1182/blood-2022-158518

Published: 2022

Journal Articles

Safety and Efficacy of FLAG-Ida Combined with Venetoclax Treatment for Newly Diagnosed and Relapsed / Refractory AML Patients- a Systematic Review

Adi Sherban, Danielle Fredman, Shai Shimony, Moshe Yeshurun, Pia Raanani, Maximilian F. Stahl, Anat Gafter-Gvili, Ofir Wolach

Blood (2022) 140 (Supplement 1): 11716–11717.

https://doi.org/10.1182/blood-2022-163152

Published: 2022

Journal Articles

Sequential Therapy Vs. Salvage Chemotherapy for Patients with AML Refractory to First Induction Regimen- a Bi-Institutional Retrospective Cohort Analysis

Ron Ram, Odelia Amit, Shai Winer, Yakir Moshe, Pia Raanani, Eitan Kugler, Moshe Yeshurun, Irit Avivi, Ofir Wolach

Blood (2022) 140 (Supplement 1): 10637–10638.

https://doi.org/10.1182/blood-2022-164543

Published: 2022

NARROW

Phase II Prospective Trial of Fixed Duration Obinutuzumab, Ibrutinib and, Venetoclax in an Elderly Cohort of Patients with Richter's Syndrome-Givers Regimen

Derivation and External Validation of a Venous Thromboembolism Risk Prediction Model in Patients with Acute Lymphoblastic Leukemia Receiving Asparaginase Therapy

Warburg-Effect Driven Lactic Acidosis Is Associated with Early Death in Patients with Lymphoma

Interferon Inhibits Netosis in Neutrophils Derived from Patients with Myeloproliferative Neoplasms in a Neutrophil Subpopulation-Specific Manner

Genotype-phenotype correlations in chronic granulomatous disease: insights from a large national cohort

Unraveling the Mechanism of Action of Bispecific T-Cell Engagers in B-Cell Acute Lymphoblastic Leukemia Using Advanced Single-Cell Multiomics

Daunorubicin/Cytarabine Liposome +/- Gemtuzumab Ozogamicin for Adult Patients with Newly Diagnosed, Low-Intermediate Risk, FLT3-Wild Type, AML: A Pilot Study

Impact of Premedication Prior to Platelet Transfusion on Platelet Increment Among Hemato-Oncological Patients

A Prospective, Phase-II Study to Evaluate the Efficacy and Safety of Obinutuzumab, Ibrutinib, and Venetoclax (GIVeRS) in Patients with Richter's Syndrome

Utility of Echocardiogram in Neutropenic Patients with Gram Positive Bacteremia: A Retrospective Study

Efficacy of Luspatercept in Low-Risk Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis

Warburg-Effect Driven Lactic Acidosis Is Associated with Early Death in Patients with Lymphoma

Gilteritinib and Venetoclax for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia - a Real-World Multicenter Retrospective Study

Thrombin Generation Is Differentially Affected By Anticoagulants in Patients with Acute Lymphoblastic Leukemia - an Ex-Vivo Study

Clinical Predictors for Relapse Among Patients with AML Who Responded to Venetoclax-Based Treatment - a Real-World Prospective Analysis from the Revive Study Group

Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By TP53 and IDH1/2 Mutation: Results from the AML Real World Evidence (ARC) Initiative

Long-Term Follow-up of the Phase 3 Viale-a Clinical Trial of Venetoclax Plus Azacitidine for Patients with Untreated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Safety and Efficacy of FLAG-Ida Combined with Venetoclax Treatment for Newly Diagnosed and Relapsed / Refractory AML Patients- a Systematic Review

Sequential Therapy Vs. Salvage Chemotherapy for Patients with AML Refractory to First Induction Regimen- a Bi-Institutional Retrospective Cohort Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only